Incorrect password
evipedia.ai Suggest Edit

Kisspeptin-10 for Health & Longevity

Evidence Review created on 04/21/2026 using AI4L / Opus 4.7

Also known as: Kp-10, KP10, KISS1 (112-121), Metastin (45-54), Kisspeptin 112-121

Motivation

Kisspeptin-10 is the ten-amino-acid tail of a larger hormone the hypothalamus uses to control downstream reproductive hormones. Acting one step upstream of the signals that release luteinizing hormone and follicle-stimulating hormone, this short peptide can nudge the reproductive axis upward without directly supplying testosterone or estrogen. Interest has grown because reproductive hormone signaling appears tied to libido, mood, and body composition across the adult lifespan.

The peptide traces back to the discovery of a metastasis-suppressor gene named KISS1, whose product later turned out to be the master switch that triggers puberty. Since then academic groups, most notably at Imperial College London, have explored kisspeptin in infertility, low libido, hypothalamic amenorrhea, and assisted-reproduction settings, while a parallel gray market has emerged for research-grade kisspeptin-10 marketed for vitality.

This review examines what is currently known about kisspeptin-10 as a health and longevity intervention, including its mechanism, the human clinical evidence, its regulatory position, its side-effect profile, and the practical considerations that shape how it is used.

Benefits - Risks - Protocol - Conclusion

A curated selection of high-quality expert commentary, narrative reviews, and news coverage providing accessible overviews of kisspeptin-10 and the broader kisspeptin system.

  • Benefits & Risks of Peptide Therapeutics for Physical & Mental Health - Andrew Huberman

    Long-form episode that discusses kisspeptin by name within the “vitality and libido” peptide category, covering its position upstream of gonadotropin-releasing hormone, luteinizing hormone, follicle-stimulating hormone, and testosterone/estrogen, and framing it as “a bit of a wild card” when used outside its narrow studied indications.

  • AMA #83: Peptides — Evaluating the Science, Safety, and Hype in a Rapidly Growing Field - Peter Attia

    Provides an evaluative framework for peptides including kisspeptin-class compounds, covering mechanism, intended effects, safety, dosing, alternatives, and the regulatory gray zone in which most injectable peptides sit despite aggressive marketing.

  • Kisspeptin hormone injection could treat low sex drive in women and men - Imperial College London

    Plain-language summary of the two 2023 JAMA Network Open randomized trials in men and women with hypoactive sexual desire disorder (HSDD, a clinical diagnosis of persistently low sexual desire causing distress), including the magnitude-of-effect findings on sexual brain processing, penile tumescence, and behavioral measures of desire, and the researchers’ own framing of next-step Phase 2 work.

  • Can a Kiss Treat Low Sexual Desire in Men and Women? - Mills and Dhillo

    Feature article in The Endocrinologist written by the investigators who ran the Imperial College London kisspeptin trials, covering the hypothalamic-pituitary-gonadal role of kisspeptin, the HSDD trial results in context, and the broader neuropeptide landscape spanning metabolism and emotional processing.

  • Functions of Galanin, Spexin and Kisspeptin in Metabolism, Mood and Behaviour - Mills et al., 2021

    Narrative review in Nature Reviews Endocrinology covering the non-reproductive actions of kisspeptin including glucose-stimulated insulin secretion, food intake, energy expenditure, sexual and emotional brain processing, and antidepressive and fear-suppressing effects, along with controversies and gaps.

No dedicated content on kisspeptin-10 was found from Rhonda Patrick (foundmyfitness.com), Chris Kresser (chriskresser.com), or Life Extension Magazine (lifeextension.com) despite direct searches on each platform for “kisspeptin” and “Kp-10.”

Grokipedia

Kisspeptin

Reference overview of the kisspeptin family including kisspeptin-10, covering the KISS1 gene and KISS1R (also called GPR54) receptor, KNDy neurons of the arcuate nucleus, the 2003 discovery of the receptor’s essential role in puberty, and the broader non-reproductive actions in metabolism, mood, cardiovascular function, and cancer biology.

Examine

No dedicated article for kisspeptin or kisspeptin-10 was found on Examine.com. Examine.com typically does not cover research peptides and prescription-adjacent compounds that lack strong human nutritional or broadly-available consumer supplement evidence.

ConsumerLab

No dedicated article for kisspeptin or kisspeptin-10 was found on ConsumerLab.com. ConsumerLab focuses on independent testing of commercially available consumer supplements and does not cover injectable research peptides that sit outside the mainstream supplement market.

Systematic Reviews

A PubMed search identified the following systematic reviews and meta-analyses relevant to kisspeptin or kisspeptin-10.

Mechanism of Action

Kisspeptin-10 is the C-terminal 10-amino-acid fragment of the 54-amino-acid parent peptide kisspeptin-54 (originally called metastin), itself cleaved from the 145-amino-acid preprokisspeptin protein encoded by the KISS1 gene. All active kisspeptins share the same C-terminal Arg-Phe-amide (RF-amide) motif that binds the kisspeptin receptor KISS1R (also known as GPR54), a G-protein-coupled receptor (a membrane protein that triggers intracellular signaling cascades).

The primary site of action is the hypothalamus, where KISS1R is expressed on gonadotropin-releasing hormone (GnRH) neurons. Binding activates the phospholipase C / inositol trisphosphate / calcium pathway inside these neurons, depolarizing them and causing pulsatile release of GnRH into the hypophyseal portal vessels. GnRH then stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which act on the testes or ovaries to produce testosterone and estradiol. Kisspeptin therefore sits one step upstream of the entire hypothalamic-pituitary-gonadal (HPG) axis and is considered its master switch. Humans with inactivating mutations in KISS1R fail to go through puberty (idiopathic hypogonadotropic hypogonadism), while activating mutations produce central precocious puberty (puberty before age 8 in girls or age 9 in boys).

Kisspeptin neurons in the arcuate nucleus, also called KNDy neurons (co-expressing kisspeptin, neurokinin B, and dynorphin), generate the GnRH pulse itself through a reciprocal neurokinin-B/dynorphin feedback loop. Kisspeptin-10 bypasses upstream modulators such as metabolic signals (leptin, insulin), stress hormones (cortisol), and sex steroids (which normally feed back on these neurons), making it capable of restoring axis function when those modulators are suppressed.

Competing mechanistic views. Animal data initially suggested kisspeptin pulses drive GnRH pulses, but clinical infusion work in humans shows that continuous receptor-saturating kisspeptin-10 still produces normal or accelerated LH pulsatility with no desensitization over 22 hours, arguing that in humans the pulse generator sits in the KNDy/neurokinin-B circuit rather than in the kisspeptin input itself. Separate work identifies KISS1R expression in white and brown adipose tissue, the pancreas, liver, and limbic brain regions, with emerging but contested roles in glucose-stimulated insulin secretion, food intake, energy expenditure, hepatic lipogenesis, and emotional/sexual processing independent of sex hormones.

Pharmacological properties of kisspeptin-10 (injectable peptide). The intravenous plasma half-life in healthy men is approximately 3.8–4 minutes, with essentially complete clearance of the parent peptide within 30 minutes of a bolus. Subcutaneous dosing produces a somewhat longer window of elevated levels but with lower peak concentrations. Kisspeptin-10 is rapidly degraded by endopeptidases (including matrix metalloproteinase-like enzymes) in plasma; elimination is primarily via proteolytic degradation rather than renal or hepatic excretion of the intact peptide. The full-length kisspeptin-54 has a plasma half-life of roughly 27 minutes, and engineered analogs such as MVT-602 extend this to 1.3–2.2 hours. No single cytochrome P450 enzyme is relevant because kisspeptin-10 is a short peptide cleaved before reaching hepatic microsomal metabolism.

Historical Context & Evolution

The KISS1 gene was discovered in 1996 by Welch and colleagues at the Pennsylvania State University College of Medicine in Hershey, Pennsylvania, as a suppressor of metastasis in melanoma cells — the gene was named KISS1 in reference to Hershey, the home of Hershey’s Kisses. The 54-amino-acid product was initially named metastin because of its apparent tumor-metastasis-suppressing properties in melanoma, breast, and other cancer cell lines.

The orphan receptor GPR54 was cloned in 2001. The breakthrough reframing came in 2003 when two independent groups (de Roux and Seminara) reported that loss-of-function mutations in GPR54 caused idiopathic hypogonadotropic hypogonadism — patients who failed to enter puberty despite having structurally normal hypothalami, pituitaries, and gonads. This established kisspeptin as the long-sought upstream activator of GnRH and reopened interest in it from an endocrine rather than oncology perspective.

From 2005 onward, groups at Imperial College London (Dhillo, Jayasena, Abbara, Comninos) and at Massachusetts General Hospital (Seminara, Chan) ran a series of human trials administering kisspeptin-10 and kisspeptin-54 to characterize their effect on LH, FSH, and testosterone secretion, first in healthy volunteers and later in patients with hypothalamic amenorrhea, type 2 diabetes, and hyperprolactinemia (elevated blood prolactin levels, which suppress reproductive hormone output). A 2014 trial by Jayasena et al. showed that kisspeptin-54 could replace human chorionic gonadotropin as the trigger for final oocyte maturation in in vitro fertilization, reducing the risk of ovarian hyperstimulation syndrome in high-risk women. This clinical program culminated in the 2022 and 2023 JAMA Network Open trials showing that kisspeptin-54 improved sexual brain processing and behavioral measures of desire in women and men with hypoactive sexual desire disorder.

Parallel to this academic program, a gray market for research-grade kisspeptin-10 emerged around 2019–2022 through online peptide vendors marketing it for libido, vitality, and fertility. The U.S. Food and Drug Administration’s Pharmacy Compounding Advisory Committee placed kisspeptin-10 in Category 2 (not eligible for patient-specific 503A compounding) at its October 2024 meeting, citing safety data limitations. No oral or injectable kisspeptin product is FDA-approved for any indication as of early 2026.

Expected Benefits

A dedicated search across PubMed, ClinicalTrials.gov, and expert commentary was performed to compile the complete benefit profile before writing this section.

Medium 🟩 🟩

Stimulation of Endogenous Luteinizing Hormone and Testosterone in Secondary Hypogonadism

Intravenous kisspeptin-10 bolus and continuous infusion robustly stimulates LH pulsatility and downstream testosterone release in men with hypogonadism of central origin, including men with type 2 diabetes-associated central hypogonadism and idiopathic hypogonadotropic hypogonadism. Unlike exogenous testosterone, kisspeptin works upstream, preserving pituitary and gonadal participation and endogenous pulsatile rhythm. Evidence basis: controlled proof-of-concept trials (George et al., 2013, n=5 men with T2DM; Chan et al., ongoing Phase 2 NCT05896293; Imperial College trials), with dog toxicology supporting the short-course dosing approach. The clinical effect size has not yet been replicated in large Phase 3 trials.

Magnitude: In men with type 2 diabetes and mild biochemical hypogonadism, an 11-hour kisspeptin-10 infusion (4 mcg/kg/h) increased LH from 3.9 to 20.7 IU/L and testosterone from 8.5 to 11.4 nmol/L (~34% rise) with restored pulse frequency.

Oocyte Maturation Trigger in In Vitro Fertilization with Lower Ovarian Hyperstimulation Syndrome Risk

Kisspeptin-54 (closely related to kisspeptin-10) can substitute for human chorionic gonadotropin (hCG, a pregnancy hormone used in fertility medicine to mimic the natural LH surge) to trigger final oocyte maturation in in vitro fertilization (IVF) cycles. Because the induced LH surge is shorter and more physiologic, it reduces the risk of ovarian hyperstimulation syndrome (OHSS, a potentially life-threatening fluid-shift complication), which occurs most often in women with polycystic ovary syndrome or high antral follicle counts. Evidence basis: phase 2 trials at Imperial College London in 60 women with polycystic ovary syndrome at high OHSS risk, reporting 95% mature-egg retrieval and high live birth rates, supported by a 2021 meta-analysis of IVF trigger methods (Zhang et al.).

Magnitude: In the Imperial series, mature eggs developed in 57 of 60 women; at the best-performing dose, pregnancy and live birth rates were roughly twice those of standard hCG in this high-risk population, with no clinically significant ovarian hyperstimulation syndrome.

Low 🟩

Improved Sexual Brain Processing and Behavioral Desire in Hypoactive Sexual Desire Disorder

In two randomized, double-blind, placebo-controlled crossover trials (one in 32 pre-menopausal women, one in 32 men), a 75-minute intravenous kisspeptin-54 infusion (1 nmol/kg/h) modulated blood-oxygen-level-dependent activity in key sexual and attraction brain circuits on functional MRI, with corresponding increases in penile tumescence in men and behavioral measures of desire in both sexes. Studies were conducted in people with the clinical diagnosis of HSDD, not in general “low libido” populations. Kisspeptin-10 was not the study peptide, but shares the same receptor and produces the same downstream effects on a shorter time course.

Magnitude: In men with HSDD, penile tumescence in response to sexual stimuli was approximately 56% greater on kisspeptin than placebo; behavioral “happiness about sex” increased 0.63 points on a validated scale (P = 0.02). Effect size in brain processing was moderate (Cohen d = 0.81).

Potential Improvements in Glucose Homeostasis and Hepatic Lipid Handling

Preclinical and a small number of human physiology studies suggest kisspeptin signaling modulates pancreatic beta-cell function and hepatic de novo lipogenesis, with kisspeptin-10 administration in rodent models of diet-induced obesity improving glucose tolerance and reducing hepatic triglyceride accumulation. In healthy humans, short infusions have been shown to potentiate glucose-stimulated insulin secretion, though the direction of the effect is inconsistent across studies. The translational step from these mechanistic signals to meaningful clinical outcomes in humans has not yet been made.

Magnitude: Not quantified in available studies.

Improvement of Secondary Amenorrhea and Restoration of Ovulation in Hypothalamic Amenorrhea

Kisspeptin-54 subcutaneous injection acutely stimulates LH and FSH in women with functional hypothalamic amenorrhea, and pulsatile subcutaneous kisspeptin can restore follicular development and ovulation in short-course protocols. Chronic twice-daily injection produces tachyphylaxis (loss of response) after a week or two, limiting long-term monotherapy use. Evidence basis: Jayasena et al. 2009, 2010 trials and ongoing NCT05896293 / NCT07224438 Phase 2 work.

Magnitude: Acute subcutaneous kisspeptin-54 in women with HA approximately doubled baseline LH; with 8-week twice-weekly dosing, LH response attenuated toward baseline, with variable effects on menstrual cyclicity.

Speculative 🟨

Testosterone declines roughly 1% per year after age 40, and a component of this decline reflects hypothalamic changes in addition to primary testicular failure. Preserved hypothalamic and pituitary response to kisspeptin-54 in healthy older men (Abbara et al., 2018) suggests the hypothalamic trigger is intact even when testicular output falls, theoretically limiting how much kisspeptin alone can restore youthful testosterone levels in most aging men. Enthusiast use of kisspeptin-10 to raise testosterone in healthy middle-aged men is therefore mechanistically plausible for the subset with central (rather than primary) dysfunction but is not supported by controlled trials in healthy older adults.

Mood and Emotional Resilience Benefits

Kisspeptin receptors are expressed in limbic brain regions (amygdala, hippocampus, cingulate cortex). Human fMRI work shows kisspeptin modulates processing of negative emotional stimuli and attraction-related brain circuits. A 2025 randomized controlled trial (Mills et al.) found that biologically active kisspeptin-54 infusion did not alter anxiety in healthy adults, complicating the “anxiolytic” framing. Animal work in Parkinson disease models suggests intranasal kisspeptin-54 may influence amygdaloid GABA signaling, but this has not been replicated in humans.

Cancer Metastasis Suppression

The KISS1 gene was first discovered as a suppressor of metastasis in melanoma and other cancers, and kisspeptin reduces cancer cell migration in vitro. Whether pharmacologic administration of kisspeptin-10 in adults would prevent or slow metastasis of existing tumors is unknown, and in some cancers (notably hormone-sensitive breast and liver cancer) kisspeptin appears to act as a tumor promoter rather than suppressor. This is a research hypothesis only.

Benefit-Modifying Factors

  • Primary vs. secondary hypogonadism: Kisspeptin-10 stimulates testosterone only when the pituitary and gonads can still respond. In primary testicular failure (elevated baseline LH and FSH with low testosterone), the testes are the bottleneck, and kisspeptin-10 will raise LH further but not necessarily testosterone.

  • KISS1R variant status: Inactivating polymorphisms in KISS1R (the kisspeptin receptor) blunt the LH response to kisspeptin-10. Activating variants may produce exaggerated responses.

  • Baseline metabolic state: Kisspeptin tone is suppressed by energy deficit, obesity, hyperprolactinemia, and chronic stress. Kisspeptin-10 administration bypasses these upstream blocks, so benefit tends to be larger in people with a functional hypothalamic “brake” (e.g., energy-deficit amenorrhea, stress-related central hypogonadism) than in healthy individuals with already-normal axis output.

  • Sex differences: The LH and FSH response to kisspeptin-10 is sexually dimorphic, with larger and more reliable LH rises in men than in women in the early follicular phase. Women show peak responsiveness during the preovulatory LH surge. Behavioral sexual-desire effects have been documented in both sexes but in separate trials.

  • Menstrual cycle phase: In premenopausal women, kisspeptin-10 response varies markedly by cycle phase. Preovulatory administration produces the largest LH surge; early follicular phase administration produces a modest response.

  • Age: Hypothalamic response to kisspeptin is preserved at least through the sixth decade in men; the limiting factor for testosterone recovery is testicular responsiveness, which declines with age.

  • Baseline prolactin: High prolactin (as in prolactinoma or medication-induced hyperprolactinemia) suppresses GnRH. Kisspeptin-10 can partly override this suppression, making it a candidate for hyperprolactinemic hypogonadism.

Potential Risks & Side Effects

A dedicated search of prescribing-like references (drugs.com, Mayo Clinic, FDA Pharmacy Compounding Advisory Committee briefing document) and clinical trial safety data was performed to compile the complete risk profile before writing this section.

Medium 🟥 🟥

Disruption of the Hypothalamic-Pituitary-Gonadal Axis with Chronic or Supraphysiologic Dosing

Continuous or repeated high-dose kisspeptin-10 can desensitize downstream GnRH and LH/FSH responses in rodent models and in some human protocols, paradoxically reducing reproductive hormone output. In women, twice-daily subcutaneous kisspeptin-54 for 8 weeks produced tachyphylaxis. The clinical concern is that unsupervised self-administration at non-physiologic doses could produce unintended axis suppression or dysregulation rather than the advertised enhancement. Evidence basis: Jayasena et al. 2009, 2010 tachyphylaxis studies; Anderson and Millar 2022 review.

Magnitude: Not quantified in available studies for healthy individuals self-dosing; tachyphylaxis observed in roughly 50–60% of chronically dosed amenorrheic women.

Subcutaneous or intramuscular injection of research-grade kisspeptin-10 can produce local redness, swelling, and transient tenderness. Intravenous infusions have produced transient flushing, lightheadedness, mild dizziness, and headache. In clinical trials using pharmaceutical-grade preparations, these reactions have been mild and self-limiting.

Magnitude: Mild injection-site reactions reported in ~10–20% of subcutaneous dosing sessions in clinical trials; serious reactions rare.

Low 🟥

Contamination, Mis-Dosing, and Endotoxin Risk from Gray-Market Supply

Research-grade kisspeptin-10 sold outside the pharmaceutical supply chain is not subject to U.S. Pharmacopeia purity, potency, or endotoxin standards. Third-party analyses of similar gray-market peptides have repeatedly found mis-labeled content, bacterial contamination, and fragments unrelated to the claimed peptide. Because kisspeptin-10 is injected, endotoxin contamination carries a particular risk of febrile reactions and sepsis.

Magnitude: Not quantified for kisspeptin-10 specifically; several published analyses of gray-market peptides have found label-content discrepancies in 20–50% of tested vials.

Exacerbation of Hormone-Sensitive Cancers

KISS1 and KISS1R expression in hormone-sensitive breast cancer and hepatocellular carcinoma has been associated with tumor-promoting rather than tumor-suppressing activity. Acute administration of kisspeptin-10 to an adult with an undetected hormone-sensitive malignancy could theoretically accelerate progression, though direct human evidence is absent. Because kisspeptin also raises estradiol in women and testosterone in men, established hormone-responsive cancers (breast, endometrial, prostate) represent a theoretical contraindication.

Magnitude: Not quantified in available studies.

Headache, Nausea, and Flushing

Reported in both clinical-trial kisspeptin-54 infusions and gray-market kisspeptin-10 self-reports. These are generally mild and resolve within hours of dosing.

Magnitude: Reported in approximately 5–15% of infusion sessions in clinical trials; dose-related.

Speculative 🟨

Effects on Mood in Vulnerable Individuals

A 2025 placebo-controlled study in healthy adults found no effect of kisspeptin-54 on anxiety or cortisol. However, kisspeptin receptors are present in limbic structures and influence emotional brain processing, raising the theoretical possibility that individuals with underlying mood disorders, post-traumatic stress disorder, or sexual trauma histories might respond atypically. No controlled data in these populations exist.

Fertility Consequences in Women Not Seeking Pregnancy

Kisspeptin-10 can promote ovulation; unanticipated pregnancy is a theoretical risk in premenopausal women using it for non-fertility indications (e.g., libido) without concurrent contraception.

Risk-Modifying Factors

  • Hormone-sensitive cancer history: Personal or family history of breast, endometrial, ovarian, or prostate cancer warrants caution given kisspeptin’s tumor-promoting potential in these tissues.

  • Baseline prolactin and pituitary imaging: Unrecognized prolactinomas can present with low libido and low testosterone; kisspeptin-10 could mask the underlying lesion without addressing it.

  • Sex differences in cycle-phase exposure: In premenopausal women, the same kisspeptin-10 dose can produce very different LH and estradiol surges depending on cycle phase; mis-timed administration can trigger unintended ovulation or disrupt cycle regularity.

  • Pre-existing cardiovascular disease: Acute increases in testosterone and estradiol from a kisspeptin-driven LH surge could have rate-pressure effects in people with uncontrolled hypertension or recent cardiac events. Clinical trials have excluded these populations.

  • Age: Older men have blunted testicular response to kisspeptin-driven LH rises, so the benefit-to-effort ratio is lower than in younger men with functional testes.

  • Liver and kidney function: Kisspeptin-10 is not metabolized through CYP450 (the cytochrome P450 family of liver enzymes responsible for most drug metabolism) or renally excreted as an intact peptide, so hepatic/renal dose adjustment is not usually discussed, but downstream hormonal effects are still subject to hepatic clearance.

  • KISS1R polymorphisms: Genetic variants in the kisspeptin receptor alter response magnitude; no commercial pharmacogenomic testing currently incorporates KISS1R.

Key Interactions & Contraindications

Prescription drug interactions:

  • Gonadotropin-releasing hormone (GnRH) agonists and antagonists (leuprolide, degarelix, cetrorelix): Additive or antagonistic effects on the HPG axis; co-administration produces unpredictable LH/FSH responses. Severity: caution (monitor hormones).

  • Exogenous sex steroids (testosterone, estradiol, progesterone): These suppress endogenous GnRH via negative feedback. Kisspeptin-10 can partially override this suppression, producing unintended increases in LH or FSH when someone is on testosterone or hormone replacement therapy. Severity: caution (supraphysiologic hormone surges).

  • Dopamine agonists (bromocriptine, cabergoline): These lower prolactin and indirectly raise kisspeptin tone; co-administration with kisspeptin-10 could produce a larger-than-expected LH response. Severity: monitor.

  • Antipsychotics and antiemetics that elevate prolactin (risperidone, haloperidol, metoclopramide): These suppress kisspeptin neurons; kisspeptin-10 can bypass but not correct the underlying elevation. Severity: monitor (address underlying cause first).

  • Neurokinin 3 receptor (NK3R) antagonists (fezolinetant, elinzanetant): Approved or investigational drugs for menopausal vasomotor symptoms that act on the same KNDy circuit. Combined use is untested. Severity: avoid outside trial settings.

  • Selective estrogen receptor modulators (SERMs) (tamoxifen, raloxifene): Mixed agonist/antagonist effects on the HPG axis may alter kisspeptin’s downstream gonadal effects. Severity: caution.

  • Clomiphene and letrozole: These raise endogenous LH and FSH via estrogen feedback modulation; additive effects with kisspeptin-10 are theoretically possible but untested. Severity: caution (supraphysiologic hormone surges).

  • Other investigational peptides (gonadorelin, hCG): Stack with kisspeptin at the same axis; overlap raises risk of supraphysiologic hormone surges and, in women, ovarian hyperstimulation. Severity: caution (ovarian hyperstimulation risk in women).

Over-the-counter medication interactions:

  • NSAIDs (ibuprofen, naproxen, aspirin) at analgesic doses: No direct pharmacological interaction documented with kisspeptin-10; however, chronic NSAID use can suppress ovulation independently and may blunt the fertility-related downstream effects of a kisspeptin-triggered LH surge. Severity: minor (may attenuate fertility endpoints).

  • Antihistamines with sedating dopamine-blocking activity (e.g., promethazine sold OTC in some markets): Can elevate prolactin and thereby suppress kisspeptin tone; may blunt expected LH response. Severity: minor (monitor).

  • Melatonin: Pineal melatonin can modulate GnRH pulsatility; high-dose supplemental melatonin around dosing may dampen the LH response. Severity: minor (timing consideration).

Supplement interactions (including additive effects on the HPG axis):

  • Tongkat ali (Eurycoma longifolia) and Fadogia agrestis: Marketed as endogenous testosterone enhancers; additive effects with kisspeptin-10 could produce supraphysiologic testosterone rises in men. Severity: caution (additive testosterone elevation).

  • Ashwagandha (Withania somnifera): Lowers cortisol and can raise testosterone in men; additive effects with kisspeptin-10 on the HPG axis are possible. Severity: minor (monitor).

  • DHEA (dehydroepiandrosterone): Converts to testosterone and estradiol; stacking with kisspeptin-10 can produce supraphysiologic sex steroid concentrations. Severity: caution (additive sex steroid elevation).

  • Boron, zinc, and vitamin D at high doses: Modest effects on endogenous testosterone documented; additive with kisspeptin-10 is plausible but not well quantified. Severity: minor (additive).

  • Soy isoflavones, red clover, and other phytoestrogens at high intake: Partial estrogen receptor modulation may alter feedback on the HPG axis and the kisspeptin response. Severity: minor.

  • Chasteberry (Vitex agnus-castus): Lowers prolactin and may potentiate the LH response to kisspeptin-10 similar to pharmaceutical dopamine agonists. Severity: minor (monitor).

  • 5-HTP and high-dose tryptophan: Can raise prolactin acutely; may blunt kisspeptin’s LH response. Severity: minor.

Populations and severity classifications:

  • Populations to avoid: Pregnancy and breastfeeding; current or past hormone-sensitive cancer (breast, endometrial, ovarian, prostate); children and adolescents (pubertal timing risk); untreated prolactinoma; unstable cardiovascular disease (recent myocardial infarction <90 days, uncontrolled hypertension); premenopausal women not using contraception who do not want pregnancy. Severity: absolute contraindications for pregnancy, hormone-sensitive cancer, children/adolescents, and untreated prolactinoma; strong caution for the other listed populations.

  • Summary severity classifications: Hormone-sensitive cancers and pregnancy are absolute contraindications based on mechanism. Prolactinoma, cardiovascular instability, and combined use with exogenous testosterone or hCG warrant monitor-only caution with endocrinology supervision.

Risk Mitigation Strategies

  • Use only under medical supervision with baseline endocrine workup: Baseline LH, FSH, total and free testosterone (men) or estradiol and progesterone (women), prolactin, sex hormone-binding globulin, and thyroid-stimulating hormone prevent masking of underlying conditions such as prolactinoma or primary gonadal failure.

  • Exclude hormone-sensitive malignancy before initiation: Age-appropriate breast, endometrial, and prostate screening (mammography, clinical examination, prostate-specific antigen where indicated) reduces risk of accelerating an undetected tumor.

  • Avoid unsupervised gray-market product: Seek only pharmacy-compounded kisspeptin (where legally available) or enroll in clinical trials. Gray-market vials carry endotoxin, purity, and potency risk unmitigated by any regulatory testing.

  • Keep dosing short and pulsatile rather than continuous: Tachyphylaxis develops with sustained daily dosing. Short diagnostic-style protocols (single bolus or short infusion) preserve responsiveness and avoid axis desensitization.

  • Use reliable contraception in premenopausal women who do not intend pregnancy: Kisspeptin-10 can trigger ovulation, including in cycles when a woman believes she is not fertile.

  • Monitor LH, testosterone, and estradiol during use: Follow-up labs at 4–6 weeks capture both over- and under-response and help identify tachyphylaxis early.

  • Discontinue before any hormonal cancer screening: Elevated estradiol or testosterone from recent dosing can alter screening interpretation; stopping dosing for at least two weeks before prostate-specific antigen testing or mammography is prudent.

  • Avoid co-administration with other HPG-axis peptides (hCG, gonadorelin, clomiphene) without explicit endocrinology oversight: Stacking increases the risk of supraphysiologic hormone surges and, in women, ovarian hyperstimulation.

Therapeutic Protocol

No FDA-approved clinical protocol exists for kisspeptin-10 in healthy adults. The following summarizes regimens used by leading clinical investigators and reported in the peptide-clinician community.

Imperial College London / Massachusetts General Hospital investigational protocols (in controlled research settings):

  • Intravenous bolus: 0.3 mcg/kg as a single dose, used primarily for diagnostic GnRH axis testing.
  • Continuous intravenous infusion: 0.1 to 1.0 nmol/kg/h for 75 minutes to 11 hours, used for mechanistic studies and HSDD trials.
  • Subcutaneous pulsatile: 6.4 nmol/kg every 90 minutes to 3 hours via a wearable pump, used in hypothalamic amenorrhea Phase 2 trials.

Peptide-clinician / gray-market protocols (not supported by controlled trials):

  • Subcutaneous bolus: 100–200 mcg (approximately 1–3 mcg/kg) once every 2–3 days for 4–8 weeks. Some clinicians follow an “on 5 days, off 2 days” cycle; others use once-weekly dosing to avoid tachyphylaxis.

Competing approaches. The conventional approach to secondary hypogonadism in men is testosterone replacement therapy (testosterone esters, gels, or pellets), which directly supplies the downstream hormone but suppresses endogenous pulsatility and can impair spermatogenesis. Clomiphene citrate and enclomiphene are oral SERMs used off-label to stimulate endogenous testosterone and are accessible and well-studied. hCG stimulates the testes directly. Kisspeptin-10 is positioned upstream of all of these; the trade-off is that it is injectable, short-acting, and unapproved outside clinical trials.

Best time of day. LH pulse amplitude is highest in the morning in men, and morning dosing is the convention in clinical trials. Dosing in the evening is less well characterized and may interact with the normal nighttime LH pattern.

Half-life and dose splitting. Kisspeptin-10’s 4-minute plasma half-life means bolus dosing produces a sharp LH spike rather than sustained exposure. Splitting a daily dose is not typically useful; the biological LH response lasts several hours after kisspeptin-10 has already cleared. Longer-acting alternatives (kisspeptin-54, MVT-602) are being developed in clinical trials but are not available outside those trials.

Genetic polymorphisms. No routine pharmacogenomic testing is done in practice; research protocols have not tied dose choice to KISS1R variants.

Sex-based differences. Men generally show larger and more consistent LH responses across the day. Premenopausal women show cycle-phase dependence (largest response preovulatory), and responses during menopause are smaller. Postmenopausal protocols have not been established.

Age-related considerations. In men over 60, hypothalamic responsiveness is preserved, but testicular response is attenuated. Effective kisspeptin-driven testosterone rises require functioning Leydig cells.

Baseline biomarker levels. Pretreatment estradiol, progesterone, prolactin, and LH/FSH shape the expected response; clinical trials have excluded prolactin >25 ng/mL and primary hypogonadism.

Pre-existing conditions. Polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and type 2 diabetes-associated central hypogonadism are the conditions where kisspeptin-10 has been most studied. Obesity blunts endogenous kisspeptin tone but does not eliminate response to exogenous administration.

Discontinuation & Cycling

  • Long-term vs. short-term use: All published human use of kisspeptin-10 has been short-course (days to weeks). Chronic daily use is not supported by evidence and is associated with tachyphylaxis.

  • Withdrawal effects: Abrupt discontinuation does not produce the withdrawal syndromes seen with exogenous testosterone, because kisspeptin-10 works via endogenous pathways. However, the LH and testosterone rise ends within hours of the last dose, so any subjective benefit will also end rapidly.

  • Tapering: Formal tapering is not required for short-course protocols. After long-course dosing (weeks), a 2–4 week off period is reasonable to restore native pulse-generator sensitivity.

  • Cycling: Because tachyphylaxis develops with sustained daily dosing, cycling (e.g., 4–8 weeks on, 4 weeks off) is the common gray-market approach. This has not been validated in controlled trials for any endpoint.

Sourcing and Quality

  • Regulatory status and legitimate access: Kisspeptin-10 is not FDA-approved for any indication in the United States. The U.S. Pharmacy Compounding Advisory Committee placed it in Category 2 in October 2024, meaning it is not eligible for routine patient-specific 503A compounding. The only clearly legitimate access routes are (a) enrollment in a clinical trial or (b) an Investigational New Drug (IND) protocol.

  • Gray-market quality concerns: Online peptide vendors sell research-grade kisspeptin-10 labeled “not for human use.” These vials are not produced under pharmaceutical Good Manufacturing Practice (GMP) conditions and are not subject to independent purity, potency, or endotoxin testing.

  • Third-party testing: A few peptide retailers publish Certificates of Analysis from independent laboratories. These typically report peptide purity by HPLC but do not address endotoxin, sterility, or clinically relevant impurities.

  • Reputable compounding pharmacies: U.S. 503A pharmacies are not currently permitted to compound kisspeptin-10 for individual patient prescriptions. Outside the United States, availability varies and typically is still outside standard pharmacy channels.

  • Storage and reconstitution: Lyophilized kisspeptin-10 is typically stable at -20°C for at least 12 months; once reconstituted in bacteriostatic water, it is typically used within 2–4 weeks when refrigerated.

Practical Considerations

  • Time to effect: LH rises within 15–30 minutes of an IV bolus or subcutaneous injection and peaks within 1–3 hours. Downstream testosterone or estradiol changes follow within hours. Subjective effects on libido in HSDD trials were measured during the infusion itself.

  • Common pitfalls: Using kisspeptin-10 as a substitute for addressing underlying causes of low libido (poor sleep, relationship issues, medication side effects, depression, untreated hypothyroidism). Buying gray-market product and injecting without baseline endocrine evaluation. Stacking with hCG or testosterone without monitoring, producing supraphysiologic surges.

  • Regulatory status: Not FDA-approved for any indication. Not eligible for 503A compounding as of early 2026. Possession for personal use is in a legal gray zone in the United States. Use outside a clinical trial carries both regulatory and medical risk.

  • Cost and accessibility: Gray-market research-grade 10 mg vials retail for approximately $150–250. A typical twice-weekly 200 mcg protocol would cost roughly $50–100/month in raw peptide but does not include the medical oversight, labs, and injection supplies required for safe use.

  • Administration route: Subcutaneous injection is the common gray-market route. Intravenous infusion is required for controlled-drug-exposure research protocols. Oral kisspeptin-10 is not bioavailable.

  • Storage: Refrigeration after reconstitution; cold-chain handling is not guaranteed in gray-market supply.

Interaction with Foundational Habits

  • Sleep: The LH pulse generator is entrained to the sleep-wake cycle, with pulse amplitude highest in early morning after sleep onset. Chronic sleep restriction suppresses LH pulsatility and testosterone. Kisspeptin-10 can transiently override this suppression but does not address the underlying sleep deficit. Poor sleep blunts the expected testosterone response to any upstream HPG-axis intervention.

  • Nutrition: Energy deficit (eating 30% or more below maintenance), carbohydrate restriction at very low levels, and critically low body fat all suppress endogenous kisspeptin and GnRH. Kisspeptin-10 bypasses this brake acutely but not chronically, so the benefit fades if energy intake remains too low. Adequate protein intake (1.6+ g/kg) and energy balance are prerequisites for sustained reproductive hormone output.

  • Exercise: Moderate resistance training supports endogenous testosterone. Excessive endurance training (chronic energy deficit) produces “exercise hypogonadal male condition” and functional hypothalamic amenorrhea in women, both of which suppress upstream kisspeptin tone. Kisspeptin-10 has not been studied as a counter-measure to overtraining, and the correct fix is usually to restore energy availability rather than force the axis pharmacologically.

  • Stress management: Chronic psychological stress elevates cortisol and suppresses GnRH via kisspeptin neuron modulation. Kisspeptin-10 has not been shown to alter cortisol. Stress reduction practices (sleep, meditation, managing external demands) treat the upstream cause that kisspeptin-10 only temporarily overrides.

Monitoring Protocol & Defining Success

Baseline testing before starting any kisspeptin-10 regimen establishes both safety (ruling out prolactinoma, primary hypogonadism, hormone-sensitive cancer) and a reference point for tracking response.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Luteinizing Hormone (LH) 1.7–8.6 IU/L (men); cycle-dependent (women) Direct downstream readout of kisspeptin action on the pituitary Draw in the morning, fasting preferred; in women, note cycle day
Follicle-Stimulating Hormone (FSH) 1.5–12.4 IU/L (men); cycle-dependent (women) Paired reading with LH to distinguish axis response from isolated LH surge Draw with LH
Total Testosterone 600–900 ng/dL (men); 15–70 ng/dL (women) Main downstream effect of kisspeptin in men; indicator of response Morning draw, fasting; conventional reference range starts at 264 ng/dL but functional range for healthy middle-aged men runs higher
Free Testosterone 70–175 pg/mL (men) The bioavailable fraction; can change even when total testosterone does not Calculated or measured directly by equilibrium dialysis
Sex Hormone-Binding Globulin (SHBG) 20–50 nmol/L (men); 30–90 nmol/L (women) Modifies interpretation of total testosterone Affected by insulin, thyroid, liver function
Estradiol (E2) 20–40 pg/mL (men); cycle-dependent (women) Aromatized from testosterone; increases with LH-driven testosterone rises Use sensitive (LC-MS) assay at low concentrations
Prolactin <20 ng/mL (men); <25 ng/mL (women) Hyperprolactinemia suppresses kisspeptin/GnRH; must be ruled out before initiation Morning draw; fasting optional
Thyroid-Stimulating Hormone (TSH) 0.5–2.0 mIU/L Hypothyroidism mimics low-libido symptoms and can be missed Functional range is tighter than conventional range of 0.45–4.5 mIU/L
Complete Blood Count (CBC) Hematocrit <50% (men) Testosterone-driven erythrocytosis is a risk when testosterone rises rapidly Erythrocytosis = abnormally high red blood cell count; conventional range for hematocrit is 38.3–48.6% (men); >54% is a red flag
Comprehensive Metabolic Panel (CMP) Normal liver and kidney function General safety screen including liver enzymes and eGFR (estimated glomerular filtration rate, a kidney function measure) Fasting draw

Cadence: Baseline within 4 weeks of initiation. During active dosing, repeat LH, total testosterone (men) or estradiol and progesterone (women), and prolactin at 4–6 weeks. Then every 3 months if dosing continues, or 4 weeks after any protocol change.

Qualitative markers:

  • Subjective libido and sexual function (validated instruments such as FSFI for women, IIEF-5 for men)
  • Energy, motivation, and mood
  • Sleep quality and morning erections (in men)
  • Menstrual regularity (in premenopausal women)
  • Body composition trends over 3–6 months

Emerging Research

  • Phase 2 trial in idiopathic hypogonadotropic hypogonadism (IHH): NCT05896293, recruiting 36 men and women with IHH, subcutaneous pulsatile kisspeptin 112–121 (identical to kisspeptin-10) vs. leuprolide acetate, primary endpoints include LH pulse generation and ovarian follicular growth.

  • Phase 2 trial in functional hypothalamic amenorrhea (HA): NCT07224438, recruiting 20 women, two-week subcutaneous pulsatile kisspeptin-10, primary endpoints include restoration of ovulation and LH pulse patterns.

  • Phase 1 case-control study of kisspeptin in post-COVID-19 syndrome: NCT07224490, enrolling 40 participants for single IV kisspeptin-10 bolus to compare GnRH neuronal function in individuals with and without post-COVID-19 syndrome.

  • Ongoing reproductive-hormone dosing study: NCT02081924, 76 participants, 8-day monthly administration of kisspeptin 0.1, 0.3, or 1.0 nmol/kg/hour vs. saline to characterize sustained-exposure reproductive hormone responses.

  • Long-acting kisspeptin analogs: MVT-602 (Myovant Sciences), a kisspeptin receptor agonist with 1.3–2.2 hour half-life, is in clinical trials for infertility and reproductive dysfunction. Bioengineered kisspeptins with 1.5+ hour half-life (e.g., HSK-1) are in preclinical development.

  • NK3R antagonists as adjacent evidence: Elinzanetant: First Approval — Lee, 2026. Elinzanetant was approved in 2025 for menopausal vasomotor symptoms by acting on the same KNDy (kisspeptin/neurokinin B/dynorphin) circuit. Parallel evidence that manipulating this system is tractable pharmacologically.

  • Kisspeptin and metabolic-dysfunction-associated steatotic liver disease (MASLD): Kisspeptin Mitigates Hepatic De Novo Lipogenesis in MASLD — Izarraras et al., 2025. Preclinical study suggesting kisspeptin signaling reduces hepatic lipogenesis, opening a potential non-reproductive therapeutic direction.

  • Critical evidence that could weaken the case: The 2025 Kisspeptin Administration Stimulates Reproductive Hormones but Does Not Affect Anxiety in Humans RCT by Mills et al. in J Clin Endocrinol Metab did not reproduce the anxiolytic signal suggested by animal work, challenging the “mood-enhancing” rationale often used to market kisspeptin-10.

Conclusion

Kisspeptin-10 is the shortest active fragment of a brain hormone sitting at the top of the reproductive hormone cascade. Human clinical work over the past 15 years, largely from Imperial College London and Massachusetts General Hospital, has shown that short-course administration reliably raises reproductive hormone output when the axis is suppressed by brain-origin rather than gonadal causes, including certain diabetes-related and congenital cases, menstrual loss tied to energy stress, and high-prolactin states. Randomized trials in adults with clinically diagnosed low sexual desire have shown measurable effects on sexual brain processing and behavioral markers of desire in women and men, while its use in assisted reproduction has reduced ovarian overstimulation risk in clinical series.

The evidence supporting kisspeptin-10 for healthy middle-aged adults seeking general vitality or libido benefits is much thinner. Most positive trials used the longer kisspeptin-54, not kisspeptin-10, and focused on defined clinical conditions rather than optimization. Age-related testosterone decline is driven substantially by testicular rather than hypothalamic failure, limiting how much an upstream peptide can correct. The evidence base is produced by a small number of academic groups, with essentially no pharmaceutical industry investment in kisspeptin-10 itself because its short half-life makes it commercially less attractive than long-acting analogs. Regulatory status in the United States is unresolved, the gray-market supply is not quality-controlled, and chronic dosing induces tachyphylaxis. For a condition for which kisspeptin-10 is clinically indicated, the signal is real; for general longevity optimization, the evidence does not yet support claims being made in marketing.

Top - Benefits - Risks - Protocol